Linked e-resources
Details
Table of Contents
Intro; Preface; Contents; Editors and Contributors; 1 Introduction; Abstract; 1.1 Objective of This Book; 1.2 Pharmaceutical Products; 1.3 Relevance of Particle and Powder Characteristics for Product Quality; 1.4 Particle, Powder and Liquid Dispersion Characteristics [54-56, 58]; 1.4.1 Composition; 1.4.2 Particle Size and Particle Size Distribution (PSD); 1.4.3 Particle Shape; 1.4.4 Particle Morphology; 1.4.5 Particle Density and Porosity; 1.4.6 Surface Area; 1.4.7 Wettability; 1.4.8 Zeta Potential; 1.4.9 Powder Packing, Density and Porosity; 1.4.10 Powder Flowability; 1.4.11 Segregation
1.4.12 Rheology of Emulsions and Suspensions [55, 60]1.4.13 Stability of Emulsions and Suspensions [55, 60]; 1.5 Measurement Methods and Techniques [52, 54, 55]; 1.5.1 Sampling [39, 57, 70]; 1.5.2 Dispersion/Dilution [40, 58]; 1.5.3 Measurement Techniques for API Concentration and Coating; 1.5.4 Measurement Techniques for Particle Characteristics; 1.5.4.1 True Skeleton Density; 1.5.4.2 Crystallinity and Crystal Structure; 1.5.4.3 Elemental Analysis; 1.5.4.4 Particle Size Distribution (PSD); 1.5.4.5 Particle Shape; 1.5.4.6 Surface Area, Porosity and Pore Size Distribution; 1.5.4.7 Wettability
1.5.4.8 Zeta Potential1.5.5 Measurement Methods for Powder Characteristics; 1.5.5.1 Bulk Density; 1.5.5.2 Flow Properties; 1.5.6 Characterization Techniques for Liquid Dispersions; 1.5.7 Characterization Techniques for Sprays; 1.6 Set up of the Book; 1.7 Definitions, Abbreviations and Symbols; References; 2 Guide to Pharmaceutical Product Quality; Abstract; 2.1 Introduction; 2.2 Quality by Design and Process Analytical Technology; 2.3 Guidelines for Quality Control of Drug Substances; 2.4 Analysis of PSD and Particle Shape and Acceptance Criteria; 2.5 Quality Management
2.6 Definitions, Abbreviations and SymbolsReferences; 3 Bio-nano: Theranostic at Cellular Level; Abstract; 3.1 Introduction; 3.2 Janus Particles, Superparticles and Core-Shell Particles; 3.2.1 Janus-Particles; 3.2.2 Superparticles; 3.2.3 Core-Shell Particles; 3.3 Overview Drug Delivery Systems (DDS); 3.4 Surface Modification; 3.4.1 Amphiphillic Micelle Structures; 3.4.2 Multidentate Polymeric Ligands; 3.4.3 Bi-functional Ligands; 3.5 Biomedical Application-Diagnostics and Therapy; 3.5.1 Magnetic Resonance Imaging (MRI); 3.5.2 Hyperthermia; 3.5.3 Computed Tomography (CT)
3.5.4 Photothermal and Photodynamic Therapy3.6 Tumor Microenvironment; 3.7 Biodistribution and Functionalization of the DDS; 3.8 Bio-nano Interface; 3.9 Electronic Properties of Nanomaterials; 3.9.1 Luminescence of Quantum Dots; 3.10 Nanoparticles as Enzyme Mimetics; 3.11 Protein Corona; 3.12 Passive and Active Targeting; 3.13 Endocytose; 3.14 Gatekeeper; 3.15 Biorelated Degradation of the DDS; 3.16 Cancer Immunotherapy; 3.17 Limitation of the DDS; 3.18 Abbreviations; References; 4 Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design; Abstract
1.4.12 Rheology of Emulsions and Suspensions [55, 60]1.4.13 Stability of Emulsions and Suspensions [55, 60]; 1.5 Measurement Methods and Techniques [52, 54, 55]; 1.5.1 Sampling [39, 57, 70]; 1.5.2 Dispersion/Dilution [40, 58]; 1.5.3 Measurement Techniques for API Concentration and Coating; 1.5.4 Measurement Techniques for Particle Characteristics; 1.5.4.1 True Skeleton Density; 1.5.4.2 Crystallinity and Crystal Structure; 1.5.4.3 Elemental Analysis; 1.5.4.4 Particle Size Distribution (PSD); 1.5.4.5 Particle Shape; 1.5.4.6 Surface Area, Porosity and Pore Size Distribution; 1.5.4.7 Wettability
1.5.4.8 Zeta Potential1.5.5 Measurement Methods for Powder Characteristics; 1.5.5.1 Bulk Density; 1.5.5.2 Flow Properties; 1.5.6 Characterization Techniques for Liquid Dispersions; 1.5.7 Characterization Techniques for Sprays; 1.6 Set up of the Book; 1.7 Definitions, Abbreviations and Symbols; References; 2 Guide to Pharmaceutical Product Quality; Abstract; 2.1 Introduction; 2.2 Quality by Design and Process Analytical Technology; 2.3 Guidelines for Quality Control of Drug Substances; 2.4 Analysis of PSD and Particle Shape and Acceptance Criteria; 2.5 Quality Management
2.6 Definitions, Abbreviations and SymbolsReferences; 3 Bio-nano: Theranostic at Cellular Level; Abstract; 3.1 Introduction; 3.2 Janus Particles, Superparticles and Core-Shell Particles; 3.2.1 Janus-Particles; 3.2.2 Superparticles; 3.2.3 Core-Shell Particles; 3.3 Overview Drug Delivery Systems (DDS); 3.4 Surface Modification; 3.4.1 Amphiphillic Micelle Structures; 3.4.2 Multidentate Polymeric Ligands; 3.4.3 Bi-functional Ligands; 3.5 Biomedical Application-Diagnostics and Therapy; 3.5.1 Magnetic Resonance Imaging (MRI); 3.5.2 Hyperthermia; 3.5.3 Computed Tomography (CT)
3.5.4 Photothermal and Photodynamic Therapy3.6 Tumor Microenvironment; 3.7 Biodistribution and Functionalization of the DDS; 3.8 Bio-nano Interface; 3.9 Electronic Properties of Nanomaterials; 3.9.1 Luminescence of Quantum Dots; 3.10 Nanoparticles as Enzyme Mimetics; 3.11 Protein Corona; 3.12 Passive and Active Targeting; 3.13 Endocytose; 3.14 Gatekeeper; 3.15 Biorelated Degradation of the DDS; 3.16 Cancer Immunotherapy; 3.17 Limitation of the DDS; 3.18 Abbreviations; References; 4 Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design; Abstract